Project Grant R01AI179037
- The National Heart, Lung, and Blood Institute awarded a $788,478 Project Grant to the University of Texas Medical Branch at Galveston effective September 1, 2025, through June 30, 2029, under the Cardiovascular Diseases Research program (CFDA 93.837). This research grant supports a four-year investigation into the role of the C-type lectin pathway in regulating macrophage immune metabolism during Mycobacterium tuberculosis (MTB) infection in the lung. The project examines how the macrophage...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University a $3.1 million Project Grant (CFDA 93.855: Allergy and Infectious Diseases Research) effective September 19, 2025, through August 31, 2029, to conduct biomedical research investigating macrophage senescence as a driver of granuloma failure and progression to necrosis in tuberculosis (TB) and TB/HIV co-infection. The research will advance scientific understanding of fundamental mechanisms underlying...
- Federal Project Grant Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $819,998 to The Regents of the University of California, San Francisco on July 16, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support a five-year research project extending through May 31, 2030. This Project Grant funds investigator-initiated biomedical research aimed at identifying and understanding host cell death mechanisms during Mycobacterium...
- Federal Project Grant Award Summary Weill Medical College of Cornell University received a $254,250 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 7, 2025 through July 31, 2027. The award supports research focused on targeted degradation of Mycobacterium tuberculosis protein kinase G (PknG) as an adjunctive therapeutic strategy to enhance macrophage-mediated...
- This five-year, $813,838 project grant from the National Institute of Allergy and Infectious Diseases will fund research into the genetic and hormonal mechanisms underlying sex differences in tuberculosis (TB) and TB-HIV coinfection. The Johns Hopkins University will investigate how X chromosome complement and sex steroid hormones impact TB pathogenesis using cellular models, animal studies, and human samples. Researchers will utilize a novel four core genotype mouse model to differentiate the...
- This Project Grant award of $162,000 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to understand the impact of the LRRK2-G2019S genetic variant on immune system function, cell death pathways, and susceptibility to chronic inflammatory diseases and infections. Specifically, the research aims to define how the LRRK2-G2019S variant promotes necroptotic cell...
- Federal Project Grant Award Summary Tufts University School of Medicine received a $156,080 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded January 29, 2026, with completion targeted for August 15, 2028. The award funds research to elucidate spatio-temporal innate immune cell modulation of Mycobacterium tuberculosis (MTB) stress response and replication heterogeneity. The...
- Grant Award Summary The University of Pennsylvania received a $194,940 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded August 12, 2025, with completion targeted for July 31, 2030. The award funds research investigating genetic determinants of tuberculosis (TB) resistance and susceptibility in human populations. The primary deliverables include discovery of human genetic...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3.18 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Sloan-Kettering Institute for Cancer Research, effective January 28, 2026, with a completion date of December 31, 2029. This research project investigates chalkophore-mediated respiratory oxidase flexibility and its role in Mycobacterium tuberculosis virulence. The funded work...
- Federal Grant Award Summary Boston Children's Hospital received a $489,500 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded August 1, 2025, with completion scheduled for July 31, 2027. The grant funds the development of physiological in vitro human lung alveolar epithelial cell organoid models derived from bronchoalveolar lavage fluid (BALF) to advance understanding of innate...
TARGETING MEDIATORS OF OXIDATIVE STRESS TO LIMIT HYPERINFLAMMATORY CELL DEATH MODALITIES DURING MYCOBACTERIUM TUBERCULOSIS INFECTION - PROJECT SUMMARY ONE OF THE BIGGEST CHALLENGES FACING THE TUBERCULOSIS FIELD IS THE HETEROGENEITY OF TB DISEASE PRESENTATION. ONLY A SMALL PERCENTAGE OF INDIVIDUALS INFECTED WITH MYCOBACTERIUM TUBERCULOSIS GO ON TO DEVELOP AN ACUTE INFECTION. WHILE SEVERAL IMPORTANT TUBERCULOSIS CO-MORBIDITIES HAVE BEEN IDENTIFIED (I.E. HIV CO-INFECTION, SMOKING, MALNU- TRITION, DIABETES), WE ARE STILL UNABLE TO ACCURATELY PREDICT WHETHER A TUBERCULOSIS PATIENT IS AT HIGH RISK FOR DEVEL- OPING SEVERE DISEASE. FOR DECADES, WE HAVE UNDERSTOOD THAT THE WAY IN WHICH MTB-INFECTED MACROPHAGES DIE PLAYS A KEY ROLE IN DICTATING MTB OUTCOMES IN VIVO. APOPTOSIS, AN "IMMUNOLOGICALLY SILENT" FORM OF CELL DEATH IS GENERALLY CONSIDERED ANTI-BACTERIAL; APOPTOSIS LIMITS BACTERIAL SPREAD AND DOES NOT RELEASE HIGH AMOUNTS OF IM- MUNOGENIC DAMPS AND PAMPS. NECROSIS, AN INFLAMMATORY FORM OF CELL DEATH, PROMOTES MTB SURVIVAL AND SPREAD AND ELICITS HARMFUL IMMUNOPATHOLOGY. ONE WOULD PREDICT THAT A TUBERCULOSIS PATIENT WITH MACROPHAGES THAT ARE PRONE TO NECROSIS WOULD BE LIKELY TO EXPERIENCE SEVERE INFLAMMATION IN RESPONSE TO MTB INFECTION. OUR PRELIMINARY DATA DEMONSTRATE THAT A COMMON HUMAN SNP IN A MITOCHONDRIAL-ASSOCIATED GENE CALLED LRRK2 PROMOTES A NEW HYPERINFLAMMATORY TYPE OF NECROSIS IN RESPONSE TO MTB INFECTION. THIS CELL DEATH WAS DUBBED GASDERMIN D-MEDIATED NECROPTOSIS, AS IT REQUIRES THE PORE FORMING PROTEIN GASDERMIN D AND RESULTS IN ACTIVA- TION OF RIPK1/RIPK3/MLKL AND CELL DEATH VIA NECROPTOSIS. THIS MUTATION (LRRK2G2019S) PROMOTES EXCESSIVE MITO- CHONDRIAL REACTIVE OXYGEN SPECIES (MTROS) PRODUCTION AND MTROS ALONE IS SUFFICIENT TO PROMOTE GASDERMIN D- MEDIATED NECROPTOSIS. BUILDING ON THESE FINDINGS, THIS PROPOSAL WILL TEST THE HYPOTHESIS THAT MITOCHONDRIAL DYSFUNCTION AND OXIDATIVE STRESS DRIVE MTB-INFECTED MACROPHAGES TO UNDERGO INFLAMMATORY FORMS OF CELL DEATH AND CONSTITUTE A NEW, IMPORTANT "CO-MORBIDITY" FOR TUBERCULOSIS PATIENTS. THE GOAL OF THIS PROPOSAL IS TO MECHANISTICALLY DEFINE HOW OXIDATIVE STRESS PROMOTES PATHOGENIC CELL DEATH MODALITIES DURING MTB INFECTION OF MACROPHAGES AND MICE. HERE, TWO MODELS OF HIGH MTROS WILL BE LEVERAGED (EXOGENOUS MTROS VIA MENADI- ONE TREATMENT AND THE HUMAN DISEASE-ASSOCIATED SNP LRRK2G2019S) TO MECHANISTICALLY DEFINE HOW OXIDATIVE STRESS CAN REPURPOSE CELL DEATH PROTEINS IN PRIMARY MURINE MACROPHAGES. AIM 1 WILL INVESTIGATE THE ABILITY OF LRRK2 KINASE ACTIVITY TO DIRECTLY ACTIVATE NECROPTOSOME PROTEINS AND PROMOTE GASDERMIN D-MEDIATED NECROPTOSIS. AIM 2 WILL DEFINE HOW VARIOUS CELLULAR STRESSES LICENSE N-GSDMD ASSOCIATION WITH MITOCHONDRIAL PHOSPHOLIPIDS TO PROMOTE GASDERMIN D-MEDIATED NECROPTOSIS. AIM 3 WILL EXAMINE THE ROLE OF LIPID OXIDATION IN DICTATING CELL DEATH MODALITY USAGE DURING MTB INFECTION. IF SUCCESSFUL, THIS PROPOSAL WILL DEFINE THE CELLULAR TRIGGERS OF HYPERINFLAM- MATORY CELL DEATH DURING MTB INFECTION OF MACROPHAGES AND IDENTIFY NOVEL POINTS FOR THERAPEUTIC INTERVENTION THAT MAY BE MORE EFFICACIOUS TO TARGET IN TB PATIENTS WITH UNDERLYING CONDITIONS OR GENETICS LINKED TO MITOCHONDRIAL DYSFUNCTION AND OXIDATIVE STRESS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 8/19/25 | ||
| Not listed | $0 | 8/19/25 | ||
| Not listed | $769.2k | 4/10/25 | ||
| Not listed | $769.2k | 4/10/25 | ||
| Not listed | $1.5m | 4/10/25 |